| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.48 | 0.08 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.08 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.08 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.09 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.062 | 0.09 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.09 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.09 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.065 | 0.09 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.09 |